Pressemeldinger Se alle 18 treff

Ny MS-pille godkjent til norske pasienter

Ny MS-pille godkjent til norske pasienter

Pressemeldinger   •   03-03-2014 10:06 CET

Statens legemiddelverk (SLV) har nå godkjent TECFIDERA® (dimetylfumarat), en ny bremsemedisin i kapselform, mot attakkvis multippel sklerose (MS). Bioteknologiselskapet Biogen Idec bekrefter at medikamentet vil være tilgjengelig på norske apotek allerede fra 1.mars.

NEW PUBLICATION OF REAL-WORLD TYSABRI® DATA SHOW SIGNIFICANT REDUCTIONS IN KEY CLINICAL MEASURES OF DISEASE ACTIVITY WITH LONGER-TERM USE

NEW PUBLICATION OF REAL-WORLD TYSABRI® DATA SHOW SIGNIFICANT REDUCTIONS IN KEY CLINICAL MEASURES OF DISEASE ACTIVITY WITH LONGER-TERM USE

Pressemeldinger   •   03-03-2014 09:41 CET

– Five-year interim analysis from the TYSABRI Observational Program confirmed TYSABRI Overall Safety – Analysis Showed TYSABRI Use Earlier in the Course of RRMS Treatment Reduced Clinical Disease Activity; Low Probability of Disease Progression Also Demonstrated

TECFIDERA® (DIMETHYL FUMARATE) APPROVED IN THE EUROPEAN UNION AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS

TECFIDERA® (DIMETHYL FUMARATE) APPROVED IN THE EUROPEAN UNION AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS

Pressemeldinger   •   03-02-2014 17:17 CET

- Biogen Idec to Begin Launching TECFIDERA in Initial EU Countries in the Coming Weeks -

CHMP DETERMINES DIMETHYL FUMARATE IN TECFIDERA® TO BE A NEW ACTIVE SUBSTANCE IN THE EUROPEAN UNION

CHMP DETERMINES DIMETHYL FUMARATE IN TECFIDERA® TO BE A NEW ACTIVE SUBSTANCE IN THE EUROPEAN UNION

Pressemeldinger   •   25-11-2013 14:58 CET

Assessment Follows March 2013 Positive Opinion for TECFIDERA as a First-line Treatment for Multiple Sclerosis - - European Commission Decision Anticipated -

Bilder 2 treff

Oppskaket dame

Oppskaket dame

Lisens Creative Commons navngivelse
Last ned
Størrelse

6.82 KB • 43 x 63 px

Mann på benk

Mann på benk

Lisens Creative Commons navngivelse
Last ned
Størrelse

2.27 MB • 3866 x 2577 px

Dokumenter 2 treff

Biogen Idec Pipeline

Biogen Idec Pipeline

Dokumenter   •   06-05-2011 14:31 CEST

BIIB image

BIIB image

Dokumenter   •   06-05-2011 14:31 CEST

Kontaktpersoner 1 treff

  • Pressekontakt
  • Medisinsk sjef
  • MS-nevrologi
  • qaglenn.guesndmkhlersen@ombigiogenidec.cebkqom
  • 95229513
  • 23005254
Medisinsk ansvarlig for Biogen Idec's legemiddel portefølje, klinisk forskning og regulatoriske oppgaver

You haven't completed the steps for your Hosted Newsroom

You haven't entered a correct link to your helper.html file for your Hosted Newsroom. Go to Publish and complete the steps.